Table 4 Treatment effects for all contrast in terms of HAQ-DI along with 95% credible interval and probability that treatment is better than the comparator
Intervention | Comparator | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Placebo | MTX | aTNF | Tocilizumab | aTNF + MTX | Abatacept + MTX | Anakinra + MTX | Tocilizumab + MTX | ||
Placebo | Estimate | 0 | 0.28 | 0.37 | 0.53 | 0.58 | 0.49 | 0.39 | 0.55 |
95% CrI | (-0.05, 0.62) | (0.22, 0.53) | (0.27, 0.79) | (0.24, 0.93) | (0.13, 0.87) | (0.02, 0.77) | (0.25, 0.86) | ||
P(better) | 5% | <1% | <1% | <1% | 1% | 2% | <1% | ||
MTX | Estimate | -0.28 | 0 | 0.09 | 0.25 | 0.30 | 0.21 | 0.11 | 0.27 |
95% CrI | (-0.62, 0.05) | (-0.22, 0.39) | (0.03, 0.47) | (0.22, 0.37) | (0.05, 0.37) | (-0.05, 0.26) | (0.12, 0.42) | ||
P(better) | 95% | 27% | 2% | <1% | 1% | 6% | <1% | ||
aTNF | Estimate | -0.37 | -0.09 | 0 | 0.16 | 0.21 | 0.12 | 0.02 | 0.18 |
95% CrI | (-0.53, -0.22) | (-0.39, 0.22) | (-0.05, 0.37) | (-0.1, 0.52) | (-0.21, 0.47) | (-0.32, 0.36) | (-0.08, 0.44) | ||
P(better) | >99% | 73% | 6% | 8% | 23% | 46% | 8% | ||
Tocilizumab | Estimate | -0.53 | -0.25 | -0.16 | 0 | 0.05 | -0.04 | -0.14 | 0.02 |
95% CrI | (-0.79, -0.27) | (-0.47, -0.03) | (-0.37, 0.05) | (-0.18, 0.28) | (-0.3, 0.24) | (-0.41, 0.13) | (-0.14, 0.18) | ||
P(better) | >99% | 98% | 94% | 32% | 63% | 88% | 39% | ||
aTNF + MTX | Estimate | -0.58 | -0.30 | -0.21 | -0.05 | 0 | -0.09 | -0.19 | -0.03 |
95% CrI | (-0.93, -0.24) | (-0.37, -0.22) | (-0.52, 0.10) | (-0.28, 0.18) | (-0.26, 0.09) | (-0.36, -0.02) | (-0.19, 0.14) | ||
P(better) | >99% | >99% | 92% | 68% | 85% | 98% | 65% | ||
Abatacept + MTX | Estimate | -0.49 | -0.21 | -0.12 | 0.04 | 0.09 | 0 | -0.10 | 0.06 |
95% CrI | (-0.87, -0.13) | (-0.37, -0.05) | (-0.47, 0.21) | (-0.24, 0.30) | (-0.09, 0.26) | (-0.33, 0.12) | (-0.16, 0.27) | ||
P(better) | 99% | 99% | 77% | 37% | 15% | 84% | 28% | ||
Anakinra + MTX | Estimate | -0.39 | -0.11 | -0.02 | 0.14 | 0.19 | 0.10 | 0 | 0.16 |
95% CrI | (-0.77, -0.02) | (-0.26, 0.05) | (-0.36, 0.32) | (-0.13, 0.41) | (0.02, 0.36) | (-0.12, 0.33) | (-0.06, 0.37) | ||
P(better) | 98% | 94% | 54% | 12% | 2% | 16% | 6% | ||
Tocilizumab + MTX | Estimate | -0.55 | -0.27 | -0.18 | -0.02 | 0.03 | -0.06 | -0.16 | 0 |
95% CrI | (-0.86, -0.25) | (-0.42, -0.12) | (-0.44, 0.08) | (-0.18, 0.14) | (-0.14, 0.19) | (-0.27, 0.16) | (-0.37, 0.06) | ||
P(better) | >99% | >99% | 92% | 61% | 35% | 72% | 94% | ||